Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women (SMARTT)
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women|
- Lactic acidosis [ Time Frame: Birth, 1, 3, 5, 7, 9, 11, 13, 15, and 17 years of age. ]Assessed through the measurement of blood lactate levels using a point-of-care lactate measuring device. Venous lactate and pyruvate levels will be measured for children for whom the point-of-care lactate measurement is abnormal.
- Neurologic abnormalities [ Time Frame: Annually birth through age 5; semiannual thereafter, assessments vary based on age of child. ]Assessed via head circumference measurement and medical record review for documented clinical diagnoses of seizures, microcephaly, or other neurologic diagnosis.
- Neurodevelopmental abnormalities [ Time Frame: 1, 3, 5, 9, and 13 years of age, assessments vary based on age of child. ]Assessed via the following neurodevelopmental tests: Bayley Screener, Bayley III, WPPSI-III, BASC-2, WASI, WISC-IV, BRIEF, WIAT II.
- Abnormal growth and metabolic function [ Time Frame: Annually birth through age 5; semiannual thereafter, assessments vary based on age of child. ]Assessed through the measurement of height, weight, tricep skinfold thickness, mid-upperarm circumference measurements, insulin and glucose, and fasting lipids.
- Cardiac abnormalities [ Time Frame: Ages 3-5. ]Assessed through the administration of echocardiograms and serum biomarkers (ProBNP).
- Hearing dysfunction [ Time Frame: At age 5 and for children of all ages meeting a hearing/language trigger. ]Assessed via audiologic evaluation conducted by an audiologist.
- Language dysfunction [ Time Frame: 1, 2, 3, 5, and 9 years of age, assessments vary based on age. ]Assessed via the following language tests: MCDI, Ages and Stages Communication Scale, PPVT IV, Goldman Fristoe 2, Rice Wexler, TELD-3, TOLD-3, Woodcock, CELF IV.
- Drug Use and Sexual Activity [ Time Frame: 11, 13, 15, and 17 years of age. ]The assessment of sexual behavior and substance use will be conducted using an Audio Computer Assisted Survey Instrument (ACASI). ACASI uses computer and voice recordings so that the participant hears (through headphones) and sees (on the screen) each question and response list. The use of ACASI is proven to minimize response bias due to the presence of an interviewer.
- Abnormal organ function [ Time Frame: Birth and age one, semiannual thereafter. ]Assessed through the measurement of lipase, CPK, ALT, creatinine, glucose, LDH, BUN, WBC, PMN, lymphocytes, platelets, or hemoglobin ( ≥ Grade 3 adverse event).
- Death due to unknown medical condition [ Time Frame: Annual. ]Assessed through autopsy review.
- Maternal substance use during pregnancy [ Time Frame: Entry visit. ]Obtained via interview, toxicology report, and meconium testing.
Biospecimen Retention: Samples With DNA
|Study Start Date:||March 2007|
|Estimated Study Completion Date:||July 2020|
|Estimated Primary Completion Date:||July 2020 (Final data collection date for primary outcome measure)|
HIV-uninfected children < 12 years of age at the time of enrollment, born of HIV-infected mothers
HIV-uninfected children born of HIV-infected mothers enrolled from prior to birth through ≤ 72 hours of age
HIV-uninfected children born to a mother HIV uninfected at the time of the child's birth enrolled at 1, 3, 5, or 9 years of age(± 3 months) at the time of the study visit
Young Adult Cohort
Former Dynamic and Static Cohort participants ≥ 18 years of age.
Many antiretroviral therapy (ART) medications given to a pregnant woman cross the placenta and can be detected in the amniotic fluid and cord blood resulting in substantial fetal exposure. Therefore, there is concern about toxicity of the drugs in the fetus and infant. It is noteworthy that none of the currently approved ART medications for the prevention of maternal to fetal transmission of HIV are in Food and Drug Administration (FDA) Pregnancy Category A (no fetal risk ascertained in adequately controlled human studies). Thus, there is continued need to examine the toxicity of ART in HIV transmission prevention for the short-term toxicity of newer agents and combinations as well as the unanswered questions of longer term toxicity and subtle adverse effects.
The study will use a registry approach to conduct active surveillance among children < 12 years of age at enrollment. Occurrences of abnormalities from ART exposure in utero and/or in the first two months of life will be sought in multiple domains, including metabolic, growth, cardiac, neurologic, neurodevelopmental, behavior, language, and hearing. Clinical and laboratory data will be examined for abnormalities through a hierarchy of evaluations: adverse events (AE) will be identified → selected AEs will trigger predefined additional evaluations → significant observations will be defined as cases → a pattern of significant study-wide cases will be defined as signals. The incidence of these events of interest will be monitored over time and by ART regimen, and compared with historical data that may be suggestive of a signal. Some signals may be testable using existing and/or previously collected data, while other signals may indicate the need for additional hypothesis-driven studies outside of SMARTT.
The objectives of SMARTT are:
- To estimate the occurrence of potential ART-related toxicities through an ongoing surveillance system among HIV-uninfected children born to mothers with HIV infection with and without exposure to ART in utero and/or in the first two months of life and compare the occurrences of these outcomes with other sources of data as well as by ART exposures; and
- To actively encourage hypothesis-driven studies to confirm that the signals are due to ART exposure in utero and/or in the first two months of life. Note that the full design and execution of these studies may be beyond the scope of the SMARTT study but will be facilitated by SMARTT.
The specific aims of SMARTT are:
- To create a Static Surveillance Cohort to extend domain-specific data collection in children either 1) previously enrolled in any of the approved studies for enrollment into SMARTT; 2) previously enrolled in another pediatric HIV/AIDS cohort study with SMARTT Protocol Chair approval, or 3) not previously enrolled in an approved study but with equivalent data available in the medical record;
- To create a Dynamic Surveillance Cohort to examine domain-specific data of children newly exposed to ART in utero and/or in the first two months of life;
- To create a Young Adult Cohort to study long-term outcomes in SMARTT participants formerly enrolled in the Static and Dynamic cohorts.
- To identify a set of "triggers" for each domain that define a "signal" of possible ART toxicity and compare the occurrence of these signals with previously collected data and by ART exposure; and
- To encourage and facilitate the development of hypothesis-driven studies to evaluate whether a "signal" is the result of ART exposure in utero and/or in the first two months of life.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01310023
|Contact: Julie K Alperen, DrPHfirstname.lastname@example.org|
|Contact: Lauren E Nisotel, BSemail@example.com|
|United States, Alabama|
|University of Alabama||Recruiting|
|Birmingham, Alabama, United States, 35294|
|Principal Investigator: Marilyn Crain, MD|
|United States, California|
|University of California San Diego||Recruiting|
|La Jolla, California, United States, 92093|
|Principal Investigator: Stephen Spector, MD|
|University of Southern California||Recruiting|
|Los Angeles, California, United States, 90033|
|Principal Investigator: Toinette Frederick, PhD|
|United States, Colorado|
|University of Colorado Denver Health Sciences Center||Recruiting|
|Aurora, Colorado, United States, 80045|
|Principal Investigator: Elizabeth McFarland, MD|
|United States, Florida|
|Children's Diagnostic & Treatment Center||Recruiting|
|Fort Lauderdale, Florida, United States, 33316|
|Principal Investigator: Ana Puga, MD|
|University of Florida Health Science Center||Recruiting|
|Jacksonville, Florida, United States, 32209|
|Principal Investigator: Mobeen Rathore, MD|
|University of Miami||Recruiting|
|Miami, Florida, United States, 33136|
|Principal Investigator: Gwendolyn Scott, MD|
|United States, Illinois|
|University of Illinois, Chicago||Recruiting|
|Chicago, Illinois, United States, 60612|
|Principal Investigator: Karen Hayani, MD|
|Ann and Robert H. Lurie Children's Hospital||Recruiting|
|Chicago, Illinois, United States, 60614|
|Principal Investigator: Ram Yogev, MD|
|United States, Louisiana|
|Tulane University Health Sciences Center||Recruiting|
|New Orleans, Louisiana, United States, 70112|
|Principal Investigator: Russell Van Dyke, MD|
|United States, Maryland|
|University of Maryland||Terminated|
|Baltimore, Maryland, United States, 21201|
|United States, New Jersey|
|Rutgers - New Jersey Medical School||Recruiting|
|Newark, New Jersey, United States, 07101-1709|
|Principal Investigator: Arry Dieudonne, MD|
|United States, New York|
|Bronx Lebanon Hospital Center||Recruiting|
|Bronx, New York, United States, 10457|
|Principal Investigator: Murli Purswani, MD|
|Jacobi Medical Center||Terminated|
|Bronx, New York, United States, 10461|
|SUNY Downstate Medical Center||Recruiting|
|Brooklyn, New York, United States, 11203-2098|
|Principal Investigator: Hermann Mendez, MD|
|New York University School of Medicine||Recruiting|
|New York, New York, United States, 10016|
|Principal Investigator: William Borkowsky, MD|
|SUNY Stony Brook||Terminated|
|Stony Brook, New York, United States, 11794|
|United States, Pennsylvania|
|Children's Hospital of Philadelphia||Terminated|
|Philadelphia, Pennsylvania, United States, 19104-4318|
|United States, Tennessee|
|St. Jude Children's Research Hospital||Recruiting|
|Memphis, Tennessee, United States, 38105-2764|
|Principal Investigator: Katherine Knapp, MD|
|United States, Texas|
|Baylor College of Medicine||Recruiting|
|Houston, Texas, United States, 77030-3498|
|Principal Investigator: Wililam Shearer, MD, PhD|
|University of Puerto Rico Medical Center||Recruiting|
|San Juan, Puerto Rico, 00935|
|Principal Investigator: Zoe Rodriguez, MD|
|San Juan Research Hospital||Recruiting|
|San Juan, Puerto Rico, 00936-8344|
|Principal Investigator: Nicolas Rosario-Matos, MD|
|Principal Investigator:||George R. Seage, ScD, MPH||Harvard School of Public Health|
|Principal Investigator:||Russell Van Dyke, M.D.||Tulane University School of Medicine|